Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis

References

• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
   PubMed Web of Science ®Google Scholar
• Dall T, Mann SE, Zhang Y, et al. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20
   Google Scholar
• Hirsch IB, Atchley DH, Tsai E, et al. Ascorbic acid clearance in diabetic nephropathy. J Diabetes Complications 1998;12:259-263
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-564
   PubMedGoogle Scholar
• Caro J, Ward A, O’Brien J, et al. Impact of improving long-term glycemic control on US lifetime costs of complications. Presentation at the 61st Scientific Session of the American Diabetes Association, June 2001, Philadelphia, PA
   Google Scholar
• Edwards KL, Alvarez C, Irons BK, et al. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy 2008;28:506-521
   Google Scholar
• Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-2348
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569
   PubMed Web of Science ®Google Scholar
• Norris SL, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review. Diabet Med 2009;26:837-846
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients; a randomized controlled trial. Diabetes Care 2009;32:762-768
   PubMed Web of Science ®Google Scholar
• Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in U.S. managed care formulary decisions: a private payer’s experience. J Manag Care Pharm 2006;12:726-735
   Google Scholar
• Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-622
   PubMed Web of Science ®Google Scholar
• Misurski D, Lage MJ, Fabunmi R, et al. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy 2009;7:245-254
   PubMedGoogle Scholar
• The United States Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers (CPI-U): U.S. city average, by expenditure category and commodity and service group (table 1A). Available at: http://www.bls.gov/cpi/cpid08av.pdf. Accessed April 19, 2010
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
   PubMed Web of Science ®Google Scholar
• Bergstralh EJ, Kosanke JL. Computerized matching of controls. Section of Biostatistics Technical Report 56. Rochester, MN: Mayo Foundation; 1995
   Google Scholar
• D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281
   PubMed Web of Science ®Google Scholar
• Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286
   PubMed Web of Science ®Google Scholar
• Verge D, Lopez X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Curr Diabetes Rev 2010;6:191-200
   PubMedGoogle Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26:S18-24
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679
   PubMed Web of Science ®Google Scholar
• Tibaldi J. Initiating and intensifying insulin therapy in type 2 diabetes mellitus. Am J Med 2008;121:S20-29
   PubMed Web of Science ®Google Scholar